They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.

Your daily dose of the clinical news you may have missed.

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.

Your daily dose of the clinical news you may have missed.

von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.